These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19963374)

  • 1. Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent.
    Brown A; Brown TB; Calabrese A; Ellis D; Puhalo N; Ralph M; Watson L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):516-20. PubMed ID: 19963374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent.
    Brown A; Brown L; Brown TB; Calabrese A; Ellis D; Puhalo N; Smith CR; Wallace O; Watson L
    Bioorg Med Chem Lett; 2008 Oct; 18(19):5242-4. PubMed ID: 18778939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of amide bioisosteres of triazole oxytocin antagonists.
    Brown A; Ellis D; Wallace O; Ralph M
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2224-8. PubMed ID: 20189387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aryloxypyrazines as highly selective antagonists of Oxytocin.
    Brown A; Ellis D; Pearce D; Ralph M; Sciammetta N
    Bioorg Med Chem Lett; 2009 May; 19(10):2634-6. PubMed ID: 19376698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and optimization of potent, selective antagonists of Oxytocin.
    Brown A; Brown L; Ellis D; Puhalo N; Smith CR; Wallace O; Watson L
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4278-81. PubMed ID: 18639455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a urea bioisostere of a triazole oxytocin antagonist.
    Brown A; Ellis D; Wallace O; Ralph M
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1851-3. PubMed ID: 20172721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
    Bell IM; Erb JM; Freidinger RM; Gallicchio SN; Guare JP; Guidotti MT; Halpin RA; Hobbs DW; Homnick CF; Kuo MS; Lis EV; Mathre DJ; Michelson SR; Pawluczyk JM; Pettibone DJ; Reiss DR; Vickers S; Williams PD; Woyden CJ
    J Med Chem; 1998 Jun; 41(12):2146-63. PubMed ID: 9622556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
    J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
    Borthwick AD; Davies DE; Exall AM; Hatley RJ; Hughes JA; Irving WR; Livermore DG; Sollis SL; Nerozzi F; Valko KL; Allen MJ; Perren M; Shabbir SS; Woollard PM; Price MA
    J Med Chem; 2006 Jul; 49(14):4159-70. PubMed ID: 16821776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of spirocyclic piperidine-azetidine inverse agonists of the ghrelin receptor.
    Kung DW; Coffey SB; Jones RM; Cabral S; Jiao W; Fichtner M; Carpino PA; Rose CR; Hank RF; Lopaze MG; Swartz R; Chen HT; Hendsch Z; Posner B; Wielis CF; Manning B; Dubins J; Stock IA; Varma S; Campbell M; DeBartola D; Kosa-Maines R; Steyn SJ; McClure KF
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4281-7. PubMed ID: 22677316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
    Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
    J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency.
    Borthwick AD; Liddle J; Davies DE; Exall AM; Hamlett C; Hickey DM; Mason AM; Smith IE; Nerozzi F; Peace S; Pollard D; Sollis SL; Allen MJ; Woollard PM; Pullen MA; Westfall TD; Stanislaus DJ
    J Med Chem; 2012 Jan; 55(2):783-96. PubMed ID: 22239250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, 3D-QSAR, and docking studies of 1-phenyl-1H-1,2,3-triazoles as selective antagonists for beta3 over alpha1beta2gamma2 GABA receptors.
    Alam MS; Huang J; Ozoe F; Matsumura F; Ozoe Y
    Bioorg Med Chem; 2007 Aug; 15(15):5090-104. PubMed ID: 17544280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
    Scott JD; Miller MW; Li SW; Lin SI; Vaccaro HA; Hong L; Mullins DE; Guzzi M; Weinstein J; Hodgson RA; Varty GB; Stamford AW; Chan TY; McKittrick BA; Greenlee WJ; Priestley T; Parker EM
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6018-22. PubMed ID: 19800231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
    Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
    J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY; Wo NC; Cheng LL; Manning M
    J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New, potent, and selective peptidic oxytocin receptor agonists.
    Wiśniewski K; Alagarsamy S; Galyean R; Tariga H; Thompson D; Ly B; Wiśniewska H; Qi S; Croston G; Laporte R; Rivière PJ; Schteingart CD
    J Med Chem; 2014 Jun; 57(12):5306-17. PubMed ID: 24874785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The characterization of a novel V1b antagonist lead series.
    Smethurst CA; Borthwick JA; Gaines S; Watson S; Green A; Schulz MJ; Burton G; Buson AA; Arban R
    Bioorg Med Chem Lett; 2011 Jan; 21(1):92-6. PubMed ID: 21146408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
    Allerton CM; Barber CG; Beaumont KC; Brown DG; Cole SM; Ellis D; Lane CA; Maw GN; Mount NM; Rawson DJ; Robinson CM; Street SD; Summerhill NW
    J Med Chem; 2006 Jun; 49(12):3581-94. PubMed ID: 16759100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.